These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3773565)

  • 1. Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?
    Ye JS; Feng GH; Liang GR; Tao MX
    Leuk Res; 1986; 10(10):1221-4. PubMed ID: 3773565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute leukemia.
    Winter JN; Variakojis D; Gaynor ER; Larson RA; Miller KB
    Cancer; 1985 Aug; 56(3):443-9. PubMed ID: 3859362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine.
    Huang CL; Deng ML; Guo RJ; Wu MT; Liu FZ; Liang YM; Qiao QD
    Leukemia; 1988 Aug; 2(8):518-22. PubMed ID: 3412024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effects of low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes].
    Kanamori H; Maruta A; Fukawa H; Harano H; Kodama F; Miyashita H; Matsuzaki M; Noguchi T; Murata T; Hashimoto Y
    Rinsho Ketsueki; 1991 Feb; 32(2):108-14. PubMed ID: 2027236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Central nervous system (CNS) leukemia: the role of high dose cytarabine (HDAra-C).
    Morra E; Lazzarino M; Alessandrino EP; Inverardi D; Regazzi Bonora M; Pagnucco G; Orlandi E; Bernasconi P; Canevari A; Rondanelli R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():101-3. PubMed ID: 2713552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular and clinical pharmacology of low-dose ara-C.
    Kufe DW; Griffin JD; Spriggs DR
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients.
    Tilly H; Castaigne S; Bordessoule D; Sigaux F; Daniel MT; Monconduit M; Degos L
    Cancer; 1985 Apr; 55(8):1633-6. PubMed ID: 3978558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS; Chou TC; Andreeff M; Vale K; Clarkson BD; Young CW
    Cancer Res; 1984 Feb; 44(2):825-30. PubMed ID: 6692380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose cytosine arabinoside for treating hypocellular acute leukemia in the elderly.
    Kanamori H; Maruta A; Miyashita H; Harano H; Fukawa H; Matsuzaki M; Motomura S; Mohri H; Kodama F; Okubo T
    Am J Hematol; 1992 Jan; 39(1):52-5. PubMed ID: 1536140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dose cytosine arabinoside treatment of leukemia with special reference to the optimal number of doses].
    Sampi K; Maseki N; Kumai R; Kaneko Y; Sakurai M; Hattori M
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2595-8. PubMed ID: 2774589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose cytarabine: chromosomal findings suggesting its cytostatic as well as differentiating effect.
    Hossfeld DK; Weh HJ; Kleeberg UR
    Leuk Res; 1985; 9(2):329-30. PubMed ID: 3990338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
    Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
    Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of low dose Ara-C regimen in acute leukemias and RAEB].
    Kohno T; Nagai K; Tsukazaki K; Jinnai I; Tomonaga M; Ichimaru M; Tagawa M
    Rinsho Ketsueki; 1989 May; 30(5):638-43. PubMed ID: 2795877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone marrow changes in acute non-lymphocytic leukemia patients treated with low-dose Ara-C--implications of therapeutic mechanism].
    Lin SF; Liu HW; Chen JR; Chien CH
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1987 Sep; 3(9):612-7. PubMed ID: 3483023
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose ARA-C fails to enhance differentiation of leukaemic cells.
    Perri RT; Weisdorf DJ; Oken MM
    Br J Haematol; 1985 Apr; 59(4):697-701. PubMed ID: 3886002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does treatment with ARA-C in low dosage cause differentiation of leukemic cells?
    Castaigne S; Daniel MT; Tilly H; Herait P; Degos L
    Blood; 1983 Jul; 62(1):85-6. PubMed ID: 6860796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.
    Paciucci PA; Cuttner J; Holland JF
    Semin Oncol; 1984 Sep; 11(3 Suppl 1):36-40. PubMed ID: 6385264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.